What is it about?
We systematically identified and examined data from seven randomized controlled trials on quetiapine for treatment of psychosis in patients with parkinsonism. The mean daily dose was 103 mg per day. In terms of side effects, quetiapine was well tolerated and not associated with significant worsening of motor function. However, treatment-emergent somnolence was a common reason for study discontinuation. In terms of efficacy, quetiapine failed to demonstrate significant improvement of psychotic symptoms in patients with parkinsonism compared to placebo or clozapine.
Featured Image
Why is it important?
The best available evidence from randomized controlled trials indicates that quetiapine is not more effective than placebo for hallucinations and psychosis in patients with Parkinson's disease
Perspectives
The current evidence does not demonstrate quetiapine is superior to placebo for the treatment of hallucinations and psychosis in patients with Parkinson's disease; however it is important to note that many of the clinical studies had high dropout rates and may have been underpowered to detect a significant difference between quetiapine and placebo treated groups.
Jack Chen
Read the Original
This page is a summary of: Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism, Journal of Neuropsychiatry, March 2019, American Psychiatric Association,
DOI: 10.1176/appi.neuropsych.18080180.
You can read the full text:
Contributors
The following have contributed to this page
